Today (March 4) another meeting of the Transparency Council.
AOTMiT: Transparency Council on Parkinson's disease, epilepsy and primary hypercholesterolemia, among others
Published March 4, 2024 08:50
Źródło: AOTMiT
The agenda includes:
- Preparation of a position paper on the evaluation of the drug Ngenla (somatrogonum) within the framework of the drug program B.19. "Treatment of low-grade children with somatotropin hypopituitarism (ICD-10: E23)".
- Preparation of a position paper on the evaluation of the drug Produodopa (foslevodopum + foscarbidopum) under the drug program B.90. "Treatment of motor disorders in the course of advanced parkinson's disease (ICD-10: G.20)".
- Preparation of a position paper on the evaluation of the drug Vyndaqel (tafamidisum) under the drug program "Treatment of patients with cardiomyopathy in the course of transthyretin amyloidosis (ICD 10 E85)".
- Preparation of a position paper on the issuance of approvals for reimbursement of the foodstuff for special nutritional use Kindergen for the indication: chronic renal failure in pediatric patients.
- Preparation of a position paper on examining the appropriateness of issuing reimbursement approvals for the medicinal product Nilemdo (bempedic acid) for the indication: primary hypercholesterolemia (heterozygous familial and non-familial) in adults with statin intolerance.
- Preparation of a position on the legitimacy of issuing approvals for reimbursement of medicinal products:
- Synacthen,
- Synacthen Depot (tetracosactide)
For indications: drug-resistant epilepsy, drug-resistant epilepsy under West syndrome, drug-resistant epilepsy under Lennox-Gastaut syndrome, Kinsbourne syndrome, Landau Kleffner syndrome in pediatric and adult patients.
- Preparation of an opinion on the continuation of reimbursement coverage of drugs containing the active substance bevacizumab in the indication: treatment of diabetic macular edema (DME) (ICD-10: H36.0).
- Preparation of an opinion on the draft health policy program of the local government unit "Prevention of cancer of the lower digestive tract for people aged 50-74 years implemented in the Wielkopolska province".
Source: AOTMiT








